Genentech Presents Pivotal Phase III CLL14 Results for Venclexta in Combination with Gazyva for Chronic Lymphocytic Leukemia.
M2 PHARMA-June 6, 2019-Genentech Presents Pivotal Phase III CLL14 Results for Venclexta in Combination with Gazyva for Chronic Lymphocytic Leukemia
(C)2019 M2 COMMUNICATIONS
- US-based Genentech, a member of Switzerland's Roche Group (SIX: RO) (OTCQX: RHHBY) has presented results from the pivotal Phase III CLL14 study in previously untreated chronic lymphocytic leukemia showing that Venclexta (venetoclax) plus Gazyva (obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival, the company said.
The 12-month, fixed-duration, chemotherapy-free combination reduced the risk of disease worsening or death by 65% compared to Gazyva plus chlorambucil (PFS, as assessed by investigator; HR=0.35; 95 % CI 0.23-0.53; p
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 6, 2019|
|Previous Article:||EpimAb Biotherapeutics Raises USD 74m in Series B Financing.|
|Next Article:||Celgene Shows Data from Ongoing Studies of Liso-Cel in Patients with Difficult-to-Treat Blood Cancers at ASCO 2019.|